Post hoc REDEFINE 1 data held up in premenopausal, perimenopausal and postmenopausal women, versus low single digits on placebo.
Recap by typeshit. Full story at Simply Wall Street.
The once-daily pill blocks the IL-23 receptor and helped people with moderate to severe ulcerative colitis respond more often than placebo, a new study reports.
Bikman welcomes a new result but argues the likely cause is tirzepatide bringing insulin down rather than the drug slowing aging itself. His view, not a study claim.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Regen says the placebo group saw a 9% drop, while people on retatrutide also lost 31 lb on average and saw systolic blood pressure fall 14 points.
Industry executives say India's contract drug makers are moving past cheap small molecules into more complex products, including peptides.
A Mayo Clinic Florida study of over 3,800 women found 9.8% vs 8.2% weight loss at 9 months with HT on semaglutide. Researchers say it shows association, not cause.
Loading…